All News Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
20.35 ^USD	+0.79%		+5.39%	-26.03%

15/04	Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	MT
26/02	Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression among Patients Undergoing Active Surveillance	23/04	AQ
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024	23/04	BU
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance	22/04	BU
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024	16/04	BU
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	15/04	MT
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines	28/02	BU
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	26/02	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	23/02	MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating	23/02	MT
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell	23/02	MT
Veracyte: Q4 Earnings Snapshot	23/02	AQ
Transcript : Veracyte, Inc., Q4 2023 Earnings Call, Feb 22, 2024	23/02
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M	23/02	MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	23/02	CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results	23/02	BU
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02	CI
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference	22/02	BU
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors	14/02	CI
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	08/02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Veracyte, Inc.

Equities

VCYT

US92337F1075

All News

Filters